HOLX vs. QGEN, GEHC, COO, ALNY, GMAB, WAT, LH, AVTR, ILMN, and TEVA
Should you be buying Hologic stock or one of its competitors? The main competitors of Hologic include Qiagen (QGEN), GE HealthCare Technologies (GEHC), Cooper Companies (COO), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Waters (WAT), Laboratory Co. of America (LH), Avantor (AVTR), Illumina (ILMN), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "medical" sector.
Hologic (NASDAQ:HOLX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
Hologic received 607 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 69.66% of users gave Hologic an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Qiagen has a net margin of 17.38% compared to Hologic's net margin of 12.98%. Hologic's return on equity of 18.91% beat Qiagen's return on equity.
Hologic has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.
Hologic has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Qiagen has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.
Hologic currently has a consensus target price of $83.75, indicating a potential upside of 9.79%. Qiagen has a consensus target price of $50.95, indicating a potential upside of 19.01%. Given Qiagen's stronger consensus rating and higher possible upside, analysts clearly believe Qiagen is more favorable than Hologic.
In the previous week, Qiagen had 21 more articles in the media than Hologic. MarketBeat recorded 27 mentions for Qiagen and 6 mentions for Hologic. Hologic's average media sentiment score of 0.62 beat Qiagen's score of 0.51 indicating that Hologic is being referred to more favorably in the media.
94.7% of Hologic shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 1.8% of Hologic shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Hologic beats Qiagen on 11 of the 18 factors compared between the two stocks.
Get Hologic News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
